14 results about "Myostatin Gene" patented technology

The present application relates to an animal or cell having a myostatin gene in which 12 base pairs of the second exon are deleted. The present application may also comprise a composition capable of m

The present application relates to an animal or cell having a myostatin gene in which 12 base pairs of the second exon are deleted. The present application may also comprise a composition capable of manipulating the deletion of 12 base pairs of a myostatin gene to construct the animal or the cell. The present application also relates to use of the composition for increasing muscle.

The invention provides a method for detecting the effect of a myostatin gene in alpha-linolenic acid metabolic flux, and belongs to the technical field of gene detection. The invention provides a method for detecting the effect of a myostatin gene in alpha-linolenic acid metabolic flux, which combines gene editing and a non-targeted metabolic flux detection method to verify the effect of the Mstn gene in a target gene. Particularly, main active pathways of alpha-linolenic acid in gene editing cells and relative contribution and distribution change characteristics of the pathways are analyzed. The invention proves that the Mstn gene can regulate and control muscle growth by reducing metabolism of alpha-linolenic acid to prostaglandin E2; after the Mstn gene is knocked out, the synthesis and metabolic cycle rate of carnosine is slowed down.

This application relates to animals or cells possessing a myostatin gene, wherein 12 base pairs of the second exon of the myostatin gene are deleted. This application may also include compositions capable of manipulating the deletion of 12 base pairs of the myostatin gene to construct animals or cells. This application also relates to the use of this composition for increasing muscle mass.

A composition for modifying a myostatin gene, the composition comprising: a guide RNA; a Cas protein; wherein the target sequence is one selected from: SEQ ID NO: 38-60 and the guide sequence is one s

This invention discloses a targeted MSTN The sgRNA of the gene and its application in constructing a feline myostatin gene knockout model; the targeted MSTN The nucleotide sequence of the gene's sgRNA is shown in SEQ ID NO.1 and / or SEQ ID NO.2. This invention systematically establishes a CRISPR / Cas9 genome editing platform suitable for domestic cats for the first time and successfully constructs the world's first... MSTN The gene knockout live model in domestic cats represents a breakthrough in the technical barriers to functional gene research in domestic cats. It has been demonstrated that sgRNA is a highly efficient editing tool for the MSTN gene in domestic cats. The constructed... MSTN The gene knockout domestic cat model provides an unprecedented tool for in-depth research on muscle biology and muscle diseases in mammalian (cat) systems that are more closely related to humans. It fills the gap in large animal models in this field and has significant value for basic scientific research and translational medicine.

The invention provides an application of a myostatin gene and a mutant thereof in regulating growth and ecdysis of macrobrachium rosenbergii. Specifically, the invention discloses a promoter region 24bp mutant of a Macrobrachium rosenbergii Mstn (Mstn) gene and a function of the promoter region 24bp mutant of the Macrobrachium rosenbergii Mstn gene. An RNA interference technology proves that the mutant remarkably affects the growth speed and ecdysis cycle of shrimps by regulating muscle development and ecdysis pathways. Experiments show that the weight of the shrimps is reduced by 45.67%-66.67% due to mutant knock-down, the ecdysis period is prolonged by 4.5 days or more, and ecdysis related genes (Kr-h1, RXR and ECR) are abnormally expressed at the same time. The invention provides a new target for research on the growth and ecdysis mechanism of crustacean animals, and has application potential in aquaculture.

The present application relates to an engineered cell, an engineered protomyostatin protein, compositions comprising the same, nucleic acids encoding the same, and methods of production thereof. The engineered cells comprise a myostatin gene that is artificially modified. In some embodiments, the engineered cell expresses less myostatin mRNA as compared to a wild type cell. In addition, the engineered cell can express a mature myostatin protein having the same amino acid sequence as a wild-type animal.

We provide an animal having a myostatin gene in which 12 base pairs of exon 2 are deleted. [Solution] A transgenic animal is provided having an artificially modified myostatin gene in its genome, wherein the artificial modification is located in the second exon of the myostatin gene, and the artificial modification is a deletion of 12 base pairs in the second exon that encodes an amino acid sequence in the order of leucine, tryptophan, isoleucine, and tyrosine, compared to the amino acid sequence of myostatin in wild-type animals, and the transgenic animal expresses less myostatin gene mRNA than wild-type animals and expresses a mature myostatin protein with the same sequence as wild-type animals.

The present invention provides a novel method for inhibiting myostatin. An antisense oligonucleotide having a base length of 15 to 30, a salt thereof or a solvate thereof, the antisense oligonucleotide having a nucleotide sequence complementary to a target site of exon 1 of a myostatin gene, and being capable of inhibiting the production of mRNA of the myostatin gene. A drug, food, feed, a drug for promoting proliferation and / or hypertrophy of muscle cells, a drug for increasing muscle mass and / or inhibiting myopenia, a drug for inhibiting the production of mRNA of a myostatin gene, and a functional inhibitor of myostatin containing the antisense oligonucleotide, a salt thereof or a solvate thereof.

The application provides application of a myostatin gene and a mutant thereof in regulating growth and ecdysis of Macrobrachium rosenbergii. Specifically disclosed are a 24bp mutant of a promoter region of a Macrobrachium rosenbergii (Mstn) gene and a function thereof. It is proved by RNA interference technology that the mutant significantly affects growth speed and ecdysis cycle of shrimps by regulating muscle development and ecdysis pathways. Experiments show that knockdown of the mutant leads to a decrease of 45.67% to 66.67% in weight of the shrimps, a prolongation of more than 4.5 days in ecdysis cycle, and abnormal expression of ecdysis-related genes (Kr-h1, RXR, ECR). The application provides a new target for studying growth and ecdysis mechanism of crustaceans and has application potential in aquaculture.

The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and / or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and / or diseases or disorders that result in conditions in which muscle is adversely affected.

An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target site in exon 1 of the myostatin gene and is capable of inhibiting the production of the mRNA of the myostatin gene. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and / or hypertrophy, an agent for increasing muscle mass and / or inhibiting muscle weakness, an agent for inhibiting production of the mRNA of the myostatin gene, and an inhibitor of the function of myostatin, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.

A composition for modifying a myostatin gene, the composition comprising: a guide RNA; a Cas protein; wherein the target sequence is one selected from: SEQ ID NO: 38-60 and the guide sequence is one s